Company ProfilePremium

Jubilant Pharmova Limited (formerly Jubilant Life Sciences Ltd)

Company Profile Analysis

Tickers: JUBLPHARMA.NS, 530019.BO

ESOMAR 23 Corporate BadgeISO Certifications Badge
Jubilant Pharmova Limited - Company showcase

Year Founded & Workforce

1978

5,500 Employees

Jubilant Pharmova Limited logo

Jubilant Pharmova Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Jubilant Pharmova Limited Overview

Jubilant Pharmova is an India-domiciled, North America-centric specialty pharmaceutical and pharmaceutical-services group that has deliberately abandoned commodity chemistry in favour of high-barrier, licence-protected niches. Roughly 81% of revenue originates in the United States and 94% is denominated in US dollars — an unusual profile for an Indian mid-cap. Its economic core is radiopharmaceuticals: it is a leading North American manufacturer of SPECT diagnostic agents, operates the second-largest US radiopharmacy network (45 sites serving c.1,800 hospitals), holds a monopoly position in Iodine-131 for thyroid indications, and is the innovation leader in Rubidium-82 cardiac PET through Ruby-Fill. Adjacent to this sit the second-largest US allergenic-extract franchise (sole domestic venom supplier), a fast-scaling sterile-injectables CDMO at Spokane, Washington, an integrated Indian CRDMO, a rebuilt generics business, and an early-clinical oncology pipeline. The investment question is execution: capability is not in doubt; conversion of heavy capital deployment into returns, and durable FDA compliance, are.

MetricFY2024FY2025FY2026
Global employees (approximate)5,1005,4005,500

Note: the company discloses headcount only as an approximate global figure ("approx. 5,500") in investor materials rather than as an audited year-end number. The FY2024 and FY2025 figures above are indicative reconstructions from successive investor presentations and third-party data aggregators (TipRanks records 5,399). Precise audited year-end headcount is not publicly disclosed in a consistent series.


The company's own characterisation

Jubilant Pharmova describes itself in its FY2026 disclosures as "a company with global presence that is involved in Radiopharma, Allergy Immunotherapy, CDMO Sterile Injectables, Contract Research Development and Manufacturing Organisation (CRDMO), Generics and Proprietary Novel Drugs businesses." Its investor materials position the group as "a diversified pharmaceutical company" with a stated strategic emphasis on "specialty products and services and Dollar revenues," operating six manufacturing facilities, three research facilities, and 45 radiopharmacies, serving over 50 countries including all major regulated markets, with a workforce of approximately 5,500. The group's stated corporate values — "Caring, Sharing, Growing" — are inherited from the wider Jubilant Bhartia Group.

Independent characterisation

The self-description understates the degree to which this is really two businesses with radically different economics stapled to a venture-stage third.

Business one — the specialty franchise (Radiopharmaceuticals, Allergy Immunotherapy). These are the profit engines. Radiopharmaceutical manufacturing carried a 44% EBITDA margin in FY2026 (47% in FY2025, 50% in FY2024); Allergy Immunotherapy carried 35%. Both are protected by structural moats that have little to do with patents: radioactive isotopes decay on a timescale of hours to days, so the business is really a just-in-time logistics business wrapped around a nuclear licence. Every treatment site requires a Nuclear Regulatory Commission licence plus state, local and hospital-level approvals; authorised nuclear pharmacists require at least 4,000 hours of specialist training. Allergenic extracts sit behind an even odder moat: most of the portfolio operates under grandfathered approvals, any genuinely new product requires a Biologics License Application, and the US subcutaneous immunotherapy market has consolidated to three players. Jubilant is the sole US supplier of venom immunotherapy extracts.

Business two — the services franchise (CDMO Sterile Injectables, CRDMO). These are capital-hungry, margin-thinner, but currently growing fastest. Sterile fill-and-finish is a capacity business: contracts typically run three years or more with auto-renewal, technology transfer takes 18–24 months, switching costs are consequently very high, and 90%+ of business is repeat. Jubilant counts 5 of the top 20 global pharmaceutical companies as customers and reports a 92% customer retention rate. The Indian CRDMO arm (Jubilant Biosys) sells scientist-hours and process chemistry, with 8 of the top 20 pharma companies as clients and 85+ integrated discovery programmes delivered.

Business three — Proprietary Novel Drugs (Jubilant Therapeutics). Pre-revenue, cash-consuming (roughly ₹16 crore of EBITDA loss in FY2026), and optionality-driven.

Revenue model. Overwhelmingly product sales and manufacturing services, not licensing or subscription. Approximately 54% of FY2026 revenue was product sales (radiopharmaceuticals, radiopharmacy compounded doses, allergenic extracts, generic formulations, APIs) and approximately 36% was contract manufacturing and research services. There is essentially no royalty, milestone or subscription revenue today; the Proprietary Novel Drugs unit has explicitly stated it will "explore monetization through licensing or external fund raising," which would introduce a licensing revenue line for the first time.

Value chain position. Unusually, Jubilant occupies both the manufacturing and distribution rungs in radiopharma. It manufactures the radiopharmaceutical (Kirkland/Montreal, Canada) and compounds and distributes patient-ready doses through its own radiopharmacy network and fleet. This forward integration is the single most important structural feature of the company: it converts a product-manufacturing margin into a manufacturing-plus-distribution margin and gives the company channel control over hospital customers.

Customer types and end-markets. Hospitals, imaging centres and cardiology practices (radiopharma; c.1,800 hospitals served); allergists and ENT specialists (c.2,000 US practitioners); innovator pharmaceutical and biotechnology companies (CDMO and CRDMO); generic distributors, wholesalers and B2B2C partners in 50+ markets (generics). End-markets served: oncology diagnostics and therapy, cardiology, nephrology, pulmonology, endocrinology, allergy and immunology, cardiovascular, CNS, gastrointestinal and multi-specialty generics.

Strategy

Vision 2030 — the stated strategic frame

TargetFY2024 actualFY2030 targetLatest actual
Revenue (INR Cr)6,70313,5008,280
EBITDA margin (%)152416
Net debt (INR Cr)2,45701,751
Return on capital employedHigh single digitHigh teensHigh single digit

Jubilant Pharmova's articulated strategy is a single named programme, Vision 2030, with four hard quantitative targets measured from an FY2024 base:

Latest actuals: revenue and EBITDA margin are FY2026; net debt is as at 31 December 2025 (FY2026 year-end net debt not separately disclosed); RoCE is 9M FY2026 annualised on the company's own definition.

To hit ₹13,500 crore by FY2030 from ₹8,280 crore in FY2026 requires a 13.0% revenue CAGR over four years — achievable given FY2026 delivered 14.5%, but demanding given the FY2022–FY2026 CAGR was 7.8%. The EBITDA margin target of 23–25% requires 700–900 basis points of expansion from the FY2026 level of 15.9%, which is the genuinely hard part of the plan.

Segment-level Vision 2030 commitments

BusinessFY2024 base revenue (INR Cr)FY2030 revenue ambitionFY2030 EBITDA margin ambition
Radiopharmaceuticals952More than 2x FY2024More than 50%
Radiopharmacy2,0502x FY20247% to 8%
Allergy Immunotherapy679Approximately 1.5x FY202435% to 40%
CDMO Sterile Injectables1,117More than 2x FY2024More than 25%
CRDMO Drug Discovery Services449Approximately 3x FY2024More than 25%
CRDMO CDMO-API6452x FY2024More than 15%
Generics775Approximately 2x FY202415% to 17%

The arithmetic of the group margin target is instructive: the largest single swing factor is Radiopharmacy moving from a 1% to a 7–8% margin on a doubled revenue base — worth roughly ₹300 crore of incremental EBITDA on its own. This is why the six-site PET expansion is disproportionately important to the equity story relative to its capital cost.

Announced strategic initiatives, last 24 months

Capacity and capital projects

  1. Spokane Line 3 — US$132 million, isolator technology, +50% capacity, launched October 2025; one of the world's largest oncology products onboarded; commercial batch production late FY2027 subject to FDA approval; peak revenue potential US$80–90 million

  2. Spokane Line 4 — installation completed Q1 FY2027; technology transfer revenue from Q4 FY2027; commercial production FY2028; peak revenue potential US$80–90 million. Lines 3 and 4 together carry combined potential of US$160–180 million

  3. Montreal Line 5 (new isolator fill and finish line) — capex US$114 million with a US$35 million concessional loan; construction started, plant and machinery ordered; technology transfer revenue expected FY2029

  4. PET radiopharmacy network expansion — US$50 million (later stated as US$60m+), from 3 to 9 sites, fully operational FY2028, funded through internal accruals and long-term credit; expected asset turnover 1.0x and RoCE above 20%

  5. CRDMO capacity build — total capex US$150 million to take drug discovery from 1,000 FTEs (FY2025) to 2,000 (FY2028) to 4,000 (FY2030), including a new Devanahalli, Bengaluru site and expansions at Greater Noida and Bengaluru; expected RoCE above 20%

  6. Jubilant Biosys Noida facility — opened January 2026, multimillion-dollar, doubles overall chemistry capacity for discovery research and scale-up, with two pilot plants, targeting fee-for-service demand

Structural and portfolio moves

  1. API business transfer to Jubilant Biosys Limited — board approved 12 June 2025, completed FY2026. Rationale: house drug discovery and CDMO-API in a single entity; improve operational efficiency; build brand recall for "Jubilant Biosys" as an end-to-end CRDMO provider spanning drug discovery, early CDMO, late CDMO and commercial manufacturing; improve API asset utilisation by shifting mix toward custom manufacturing

  2. Pierre Fabre strategic partnership (France) — added a Centre of Excellence in Biologics at St Julien; expands total addressable market by US$1.4 billion in mAbs and ADCs; adds EU footprint and ADC domain expertise; integration described as complete with investment now flowing into business development

Commercial initiatives

  1. Pluvicto distribution — radiopharmacy network began distributing the leading prostate-cancer radioligand therapy during FY2026

  2. Ga-68 PSMA market expansion — extended to 38 US markets

  3. Ruby-Fill AI innovation — AI-enabled 3D cardiac blood flow quantification under development

  4. Generics relaunch programme — 6–8 new products annually, relaunching dormant ANDAs from Roorkee and the CMO network, plus in-licensing and targeted ANDA acquisition

  5. Alternate CMO development for key SPECT products, to de-risk the Montreal single-point dependency

  6. FY2025 Sustainability Report published with EY assurance; sustainability-linked loan KPIs assured by EY; targets set for renewable power share, specific GHG emissions, and specific water consumption

Innovation and monetisation

  1. Proprietary Novel Drugs monetisation — management has explicitly stated it will "explore monetization through licensing or external fund raising," with clinical data readouts expected in CY2026; the appointment of Daniel J. O'Connor is consistent with preparing for this

Management's medium-term guidance

Management has been careful to avoid specific annual revenue or EPS guidance. The concrete forward statements are:

"We expect growth momentum to strengthen in FY27": - "EBITDA margins to strengthen from H2'FY27 onwards" post-stabilisation of Montreal production, "effectively offsetting higher depreciation costs and driving net profit growth"

  • Montreal operating losses expected to taper off in H2 FY2027; segment EBITDA breakeven at Montreal targeted FY2028

  • Full SPECT product availability expected H2 FY2027; batch releases from Q2 FY2027

  • Net debt to EBITDA to remain range-bound in the near term

  • "We expect to deliver healthy revenue growth and steady margins"

Products & Services

Radiopharmaceuticals (manufactured at Kirkland/Montreal, Canada; marketed as Jubilant Radiopharma / Jubilant DraxImage)

ProductIsotope / modalityIndicationPositioning
Draximage® MAA (Macro Aggregated Albumin)Tc-99m, SPECTPerfusion phase of ventilation/perfusion (V/Q) scan for pulmonary embolismLeading player in the US market
Draximage® DTPA (Diethylenetriaminepentaacetic acid)Tc-99m, SPECTPulmonary ventilation function, used with MAA for V/Q scanLeading player in the US market; faced generic entry during FY2026
Technetium Tc-99m Sulfur Colloid InjectionTc-99m, SPECTLocalisation of metastatic lymph nodes in breast cancer and melanoma; liver, spleen and bone marrow imaging; oesophageal transit, gastro-oesophageal reflux, detection of pulmonary aspirationCore sentinel-node product
Tc-99m MertiatideTc-99m, SPECTRenal failure / renal function imagingUSFDA approval obtained FY2023; a key FY2024 growth driver
Tc-99m GluceptateTc-99m, SPECTCardiac blood pool imaging—
Tc-99m SestamibiTc-99m, SPECTCoronary artery diseaseHigh-volume cardiac agent
Tc-99m ExametazimeTc-99m, SPECTIntra-abdominal infection (labelled leukocyte imaging)—
Tc-99m MDPTc-99m, SPECTAltered osteogenesis / bone scanning—
RUBY-FILL® Rubidium Rb-82 Generator and RUBY® Rubidium Elution SystemRb-82, PETMyocardial perfusion imaging at rest or under pharmacologic stress in suspected or existing coronary artery diseaseFlagship. FDA approved 2016; mobile-use clearance received 2023. Addressable market c.US$180m growing at 12%; Jubilant share c.25% and rising. Competitive advantages: 7-week generator life versus 6 weeks for the peer product; constant activity; better image consistency; more scans per day than F-18 labelled agents; no incremental shielding capex. Install base grew 35% in FY2026 (21% in FY2025) and 26% YoY in Q1 FY2027. Product innovation underway in AI-enabled 3D cardiac blood-flow quantification
HICON® Sodium Iodide I-131 Solution USPI-131, therapeuticHyperthyroidism and selected carcinoma of the thyroidNo direct competition in the US market. Also used diagnostically
MIBG (Metaiodobenzylguanidine)I-131, therapeuticRelapsed/refractory paediatric neuroblastomaPipeline. Phase 2 dosing complete; data package to FDA Apr–Jun 2026; pre-NDA meeting targeted by Sep 2026; NDA filing H2 FY2027; launch targeted CY2027. Potential peak sales US$70–100 million
New PET and SPECT pipelineVariousVarious9 launches planned FY2027–FY2029 across a US$550 million incremental TAM with US$120 million potential peak annual sales (FY2027: 1 launch, US$30m TAM; FY2028: 4 launches, US$250m; FY2029: 4 launches, US$270m)

Pricing model: not disclosed at product level. Radiopharmaceuticals are sold on contract and per-dose bases into hospital and GPO channels.

Radiopharmacy (Jubilant Radiopharmacies division)

45 radiopharmacies: in the US (42 SPECT, 3 PET as at Q3 FY2026; the FY2024 annual report cited 46 sites comprising 43 SPECT and 3 PET), serving approximately 1,800 hospitals, with roughly 20% volume market share and six customised doses delivered every minute

  • 99%+ on-time delivery, using AI for route optimisation, with an owned delivery fleet

  • Full USP<825> compliance across the network

  • Distributes third-party products including PYLARIFY, Illuccix, Neuraceq, FDG, and — newly in FY2026 — Pluvicto (Lu-177 vipivotide tetraxetan) and Lutathera, the leading radioligand therapies for prostate and neuroendocrine cancer

  • Access strategy targets the three largest US group purchasing organisations (Premier, HealthTrust, Vizient). In FY2024, Ga-68 PSMA agent availability was extended to ten additional markets, taking total coverage to 38 markets

Expansion programme: US$50 million (subsequently described as US$60m+) to take the PET network from 3 sites to 9 sites, fully operational by FY2028, targeting 1.0x asset turnover and 20%+ RoCE

Allergy Immunotherapy (Jubilant HollisterStier, Spokane, Washington)

Product familyDescriptionPositioning
Venom extractsHoney bee and other stinging-insect venom extracts (6 venom extracts)Sole supplier in the United States
Allergenic extracts200+ allergenic extracts — dog, cat, mite, tree, pollen, mould and others2nd largest player in the US subcutaneous immunotherapy market
Skin testing devicesMultiple specialised skin-testing systemsDiagnostic complement to the therapeutic range

Brand heritage: the "HollisterStier" name is over 100 years old. Manufacturing is onshore, USFDA-approved, supported by a dedicated US sales force covering approximately 2,000 allergist and ENT customers. International markets served include Canada, Europe and Australia. Growth strategy is threefold: retain and grow US venom customers; increase allergenic-extract revenue through targeted marketing; and expand outside-US venom sales via European partnerships, alongside increased R&D in new products and technologies.

CDMO Sterile Injectables (Jubilant HollisterStier — Spokane, Washington and Kirkland/Montreal, Canada)

Service catalogue:

Sterile fill and finish: liquid and lyophilised (freeze-dried) injectables

Ophthalmic full-service offer: liquids, ointments and creams, including multi-dose preservative-free ophthalmic drops

Ampoules: - Biologics fill-finish

Non-sterile products: (Montreal)

Capacity and capability:

Spokane Line 1 and Line 2: established commercial lines; 10+ years of continuous USFDA-compliant status

Spokane Line 3: US$132 million investment, launched October 2025, isolator technology, adds 50% capacity. 10+ products in technology transfer as at Q1 FY2027, including one of the world's largest oncology products. Commercial batch production expected late FY2027 subject to USFDA approval; full utilisation in approximately 3.5 years; peak revenue potential US$80–90 million

Spokane Line 4: installation completed as at Q1 FY2027; technology-transfer revenue expected from Q4 FY2027; commercial production FY2028; peak revenue potential US$80–90 million

Montreal Line 5 (new isolator fill & finish line): construction started, plant and machinery ordered; capex US$114 million with a US$35 million concessional loan (the Government of Quebec, via Investissement Québec, previously granted a CAD 25 million loan including a CAD 6.3 million forgivable portion toward a CAD 100 million Montreal expansion). Technology-transfer revenue expected FY2029

Customer base: 5 of the top 20 global pharmaceutical companies; 25+ customers worldwide; 5+ years average relationship with top 10 customers; 90%+ repeat business; 92% customer retention. Regulatory approvals span USFDA, EMA, PMDA Japan, Health Canada, ANVISA Brazil and other authorities.

Pricing model: long-duration commercial contracts, typically three years or more with auto-renewal, plus fee-based technology transfer programmes.

CRDMO — Drug Discovery Services (Jubilant Biosys Limited)

FacilityLocationScientistsCapability
Integrated Drug Discovery Centre (IDDC)Bengaluru, Karnataka~350Target identification through candidate selection; immuno-oncology expertise
Chemistry Research Innovation Centre (CIRC)Greater Noida, Uttar Pradesh~750Synthetic, medicinal, analytical and computational chemistry
Investigational New Drug Centre (INDC)Noida, Uttar Pradesh—Preclinical CRDMO services; new discovery and preclinical facility opened January 2026 with R&D labs and two pilot plants, doubling chemistry scale-up capacity
Centre of Excellence — BiologicsSt Julien, France~35Antibody-drug conjugates, monoclonal antibodies, biologics — added via the Pierre Fabre partnership

Service lines: structural biology; computational chemistry; medicinal and synthetic chemistry; in-vitro and in-vivo biology; DMPK; toxicology; process R&D and manufacturing; ADC and mAb discovery spanning antibody engineering, linker-payload design and conjugation; complex molecule synthesis including PROTAC, PHOTAC and LYTAC.

Track record: 85+ integrated discovery programmes delivered; approximately 40 clients in the last three years; 8 of the top 20 pharmaceutical companies as customers with a 5x increase in revenue share from large pharma; 1,200+ scientists across five sites in India and Europe.

Capacity roadmap: 1,000 FTEs (FY2025) → 2,000 FTEs (FY2028) → 4,000 FTEs (FY2030), via expansion at Greater Noida and Bengaluru plus a new site at Devanahalli, Bengaluru. Total capex US$150 million with an expected RoCE above 20%.

Pricing model: fee-for-service (FFS) contracts and FTE-based engagements; management has cited growing demand specifically for FFS.

CRDMO — CDMO API (Nanjangud, Karnataka)

  • Site area approximately 267,700 square metres; six multi-stream manufacturing blocks (multi-tonne volume) plus a pilot plant (up to 20 kg); volumetric capacity approximately 785 kL; ~190 reactors ranging 0.1 kL to 15 kL; 20+ clean rooms; 900+ MT of annual capacity; over 900 personnel

  • Potent API capability across OEB Class 1–4

  • Complex chemistry expertise: chiral separation, low-temperature reactions, biotransformation, stereo-selective synthesis

  • Approvals: USFDA, PMDA Japan, KFDA Korea, ANVISA Brazil; classified VAI by USFDA following an FY2023 inspection

  • Dedicated on-site R&D centre and DoE/QbD cell; GMP kilo lab commissioned to bridge gram-to-kilogram scale-up

  • Regulatory filings (as at March 2022, the most recent comprehensive disclosure located): 98 US DMFs, 46 European CEPs, 40 Canadian DMFs, 15 Japanese DMFs, 14 Australian DMFs

Generics (Jubilant Generics Limited; Roorkee, Uttarakhand, plus CMO network; Salisbury, Maryland)

Dosage forms: immediate-release coated and uncoated tablets, bi-layered tablets, hard gelatin capsules, powder for oral suspension; NDDS-based extended/delayed/sustained release, orally disintegrating and chewable/dispersible tablets; MUPS; ophthalmics; injectables; veterinary formulations

Therapeutic areas: cardiovascular, central nervous system, gastrointestinal, multi-specialty

Geographic reach: 50+ markets including the US, Europe, Canada, Japan and Australia

R&D: Noida-based dosage development, API and BA/BE centres with 400+ scientists, supporting registrations in the US, EU, Canada, Japan, China, Australia, South Africa, Brazil and rest-of-world

Recent approvals: Dextroamphetamine Saccharate (USFDA approval, April 2026); Pantoprazole Sodium Delayed Release Oral Suspension 40 mg per packet (tentative approval 25 June 2026, final approval expected on reference-drug patent expiry in December 2026; addressable US market estimated at US$40–45 million)

Historic product of note: JUBI-R, an in-house Remdesivir lyophilised injection launched under India's emergency authorisation during the COVID-19 pandemic, with in-house API

Strategy: 6–8 new product launches annually; relaunch dormant ANDAs from Roorkee and the CMO network; in-license and acquire targeted ANDAs; build a branded India presence in diabetes, dyslipidaemia, hypertension and weight management; scale 3–4 key non-US markets on a B2B2C model

Proprietary Novel Drugs (Jubilant Therapeutics Inc., Yardley, Pennsylvania)

ProgrammeMechanismIndicationsStageUS TAM
JBI-802First-in-class oral dual inhibitor of LSD1 and HDAC6 within the CoREST complexEssential Thrombocythemia / MPN resistant to cytoreductive therapy (company-sponsored Phase II)Phase II underway; interim data expected 2026US$3.3bn
——mSTK11 IO-resistant NSCLC (investigator-led Phase II)Ongoing; early data 2026US$3.1bn
——Post-MPN AML (investigator-led Phase II)Planned; first patient in 1H 2026US$0.8bn
JBI-778Substrate-competitive, brain-penetrant PRMT5 inhibitor addressing both MTAP-null and wild-type tumoursNSCLC with EGFR mutationPhase I underway (first-in-human, India)US$2.0bn
——High-grade gliomaPhase IUS$1.7bn
——Adenoid cystic carcinoma (head and neck)Phase I—
PDL1 inhibitorsBrain-penetrant and gut-restrictiveOncology, inflammatoryPreclinical—
PAD4 inhibitorPAD4 inhibitionAutoimmune diseaseIND track—

Discovery platform: TIBEO (Therapeutic Index and Brain Exposure Optimization) — a structure-based drug design engine combining computational modelling, unique proprietary scaffolds, selectivity screening, mutation-driven cell screening, ADME with brain focus, toxicology, site-specific targeting and genetically-defined patient selection.

Both lead assets hold FDA Orphan Drug designations. Reported clinical signals for JBI-802 include a stage-IV NSCLC patient with confirmed partial response and approximately 40% tumour reduction sustained beyond two years, and a patient with over 50% shrinkage of liver metastasis with complete resolution of related portal hypertension. Scientific guidance is provided by oncologists from Memorial Sloan Kettering and Dana-Farber.

Financial Narrative

All figures consolidated, in ₹ crore unless stated, for fiscal years ended 31 March. FY2022 is the first fully comparable post-demerger year.

Company-reported EBITDA and normalised earnings: notes and sources

The company began consistently presenting a "normalised PAT" (adjusted for exceptional items and related tax) in FY2025 disclosures. FY2023 and FY2024 normalised PAT were not disclosed on a comparable basis and are shown as zero placeholders rather than estimated. FY2025 normalised PAT of ₹413 crore is derived from the disclosed 7% FY2026 growth to ₹442 crore.

Margin progression (%)

Gross profit is not separately disclosed in the company's Ind AS statutory presentation, which reports cost of materials consumed, purchases of stock-in-trade and changes in inventories as distinct lines rather than a consolidated cost of goods sold. Third-party gross-margin estimates for this company vary between 20% and 70% depending on treatment of the radiopharmacy pass-through, and are therefore not reliable and are excluded.

Net debt and leverage (company-reported, constant currency, net of deferred income on capital): notes and sources

FY2026 year-end net debt was not separately disclosed in the Q4 FY2026 release reviewed. FY2023 net debt to EBITDA was 2.93x. The FY2024 long-term capex creditors figure was not disclosed and is shown as zero placeholder. Note that reported total borrowings rose ₹884 crore in FY2026 while capex creditors also rose sharply — the balance sheet is being levered to fund the Spokane and PET build-outs.

Goodwill and intangibles are not separately disclosed in the summary balance sheet data reviewed; they are embedded within the fixed assets line. This is a genuine information gap for a company that grew historically by acquisition (Draxis, HollisterStier, Cadista).

Working capital improved materially: the cash conversion cycle compressed from 224 days in FY2022 to 47 days in FY2026, and working capital days from 56 to 13.

Ratio analysis: notes and sources

Current ratio and quick ratio are not reported here because the sources reviewed conflict materially (one aggregator reports 2.05x current ratio, another implies 1.66x on short-term assets of ₹34.6bn versus short-term liabilities of ₹20.9bn). Return on invested capital is likewise not calculated because invested-capital composition requires balance-sheet detail not available in the summary data reviewed; the company's own ROCE definition — EBIT before exceptional items divided by average of (equity plus gross debt) less (CWIP adjusted for grant) — is disclosed and its output is shown in the ROCE row above as "high single digit" for 9M FY2026 annualised, versus a Vision 2030 target of "high teens."

Commentary on trends, inflections and drivers

FY2022 — the clean baseline that immediately deteriorated. Revenue of ₹6,130 crore at an 18.8% operating margin represented the post-demerger starting point, still carrying residual COVID-era tailwinds (Remdesivir, COVID-related CDMO work). Net profit of ₹413 crore. Interest coverage of 7.9x. This was the high-water mark for margin and coverage.

FY2023 — the trough. Operating margin collapsed 640 basis points to 12.4%, the company posted a net loss of ₹65 crore, and depreciation spiked to ₹554 crore (an accelerated charge, likely impairment-related given the ₹57 crore exceptional cost flagged in Q2 FY2023). Four things went wrong simultaneously: COVID-era CDMO and generics revenue disappeared against a high base; the Roorkee import alert kept the generics business loss-making at a −18% EBITDA margin; the Montreal facility received an OAI classification; and finance costs rose 30% as leverage peaked at 0.68x debt/equity and 2.93x net debt/EBITDA. The 333% effective tax rate reflects tax charges on a near-zero pre-tax base — an arithmetic artefact, not a cash event.

FY2024 — stabilisation without recovery. Revenue grew 6.7% and reported EBITDA 20% to ₹994 crore, but net profit of only ₹73 crore against a dividend payout of ₹80 crore — a 102% payout ratio funded from reserves. Other income was negative ₹76 crore, reflecting forex and associate-level charges. Q4 FY2024 was a loss quarter (−₹62 crore net). Free cash flow of ₹83 crore against ₹888 crore of capex signalled the beginning of the heavy investment cycle.

FY2025 — the flattering year. Reported net profit of ₹836 crore (+988%) and 14.3% ROE look transformational but are almost entirely non-operating. Other income swung to +₹416 crore, driven by the Sofie Biosciences disposal gain (net exceptional income of ₹382 crore in 9M FY2025), and the effective tax rate fell to 15%. Strip these out: normalised PAT was ₹413 crore. The genuine operating achievement was real but narrower — EBITDA margin expanded 230 basis points to 17.0%, net debt halved to ₹1,348 crore using US$75 million of Sofie proceeds, and the cash conversion cycle compressed from 124 to 65 days.

FY2026 — growth purchased at the cost of margin. Revenue accelerated to +14.5%, the fastest in the post-demerger period, and EBITDA reached a record ₹1,326 crore. But EBITDA margin contracted 99 basis points to 15.9%, depreciation jumped 19% to ₹440 crore as Line 3 and other assets were capitalised, and reported net profit fell 52% to ₹398 crore against the inflated FY2025 base. Normalised PAT grew just 7% to ₹442 crore. Free cash flow was negative ₹120 crore — the second consecutive negative year — and total borrowings rose ₹884 crore. The proximate cause of the margin miss is specific and identifiable: the Montreal shutdown, which removed high-margin SPECT product supply and imposed remediation costs and under-absorption.

The inflection to watch. The company has now invested through a full cycle: CWIP has risen from ₹1,090 crore (FY2022) to ₹4,040 crore (FY2026), a 3.7x increase, while revenue rose only 35%. Roughly ₹4,000 crore of capital is sitting on the balance sheet not yet generating return. That is simultaneously the bull case (embedded operating leverage) and the bear case (a very large sum earning nothing while depreciation and interest accrue).

Q1 FY2027 — the warning shot. Revenue +17% to ₹2,229 crore, but EBITDA fell 11% to ₹268 crore, margin down 385 basis points to 11.9%, and PAT down 45% to ₹56 crore. Growth without margin is now a two-quarter pattern, not a one-quarter aberration.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Segment Revenue

SegmentFY2024FY2025FY2026

Radiopharmaceuticals

9521,0741,178

Radiopharmacy

2,0502,3142,512

Radiopharma (total)

3,0023,3883,690

Allergy Immunotherapy

679701785

CDMO Sterile Injectables

1,1171,2721,755

CRDMO Drug Discovery Services

449570654

CRDMO CDMO-API

645581563

CRDMO (total)

1,0941,1511,217

Generics

775685774

Proprietary Novel Drugs

000

Unallocable corporate income

363859

Total revenue from operations

6,7037,2348,280

Segment Revenue (FY2025–FY2026)

SegmentFY2025FY2026

Radiopharmaceuticals

12.89.7

Radiopharmacy

12.98.6

Allergy Immunotherapy

3.212.0

CDMO Sterile Injectables

13.938.0

CRDMO Drug Discovery Services

27.014.7

CRDMO CDMO-API

-9.9-3.1

Generics

-11.613.0

Total revenue from operations

7.914.5

Segment Margins & Growth (%)

SegmentFY2024FY2025FY2026

Radiopharmaceuticals

504741

Radiopharmacy

311

Allergy Immunotherapy

403535

CDMO Sterile Injectables

172318

CRDMO Drug Discovery Services

242423

CRDMO CDMO-API

101514

Generics

-18311

Group EBITDA margin (reported)

151716

Segment Revenue — Radiopharmaceuticals

SegmentFY2024FY2025FY2026

Radiopharmaceuticals

476505478

Radiopharmacy

622336

Allergy Immunotherapy

272245278

CDMO Sterile Injectables

190293314

CRDMO Drug Discovery Services

108137150

CRDMO CDMO-API

658781

Generics

-1402183

Proprietary Novel Drugs

-20-19-16

Unallocable corporate

-60-62-78

Group EBITDA (reported)

9941,2301,326

Segment Revenue — Radiopharma

SegmentFY2024FY2025FY2026

Radiopharma

44.846.844.6

Allergy Immunotherapy

10.19.79.5

CDMO Sterile Injectables

16.717.621.2

CRDMO

16.315.914.7

Generics

11.69.59.3

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from operations (INR Cr)

6,1306,2826,7037,2348,280

Total operating expenses (INR Cr)

4,9805,5035,8026,0617,020

Operating profit before other income (INR Cr)

1,1507799011,1731,260

Other income (INR Cr)

8-9-764167

Depreciation and amortisation (INR Cr)

382554382369440

Finance costs (INR Cr)

145188272240212

Profit before tax (INR Cr)

63028170981614

Effective tax rate (%)

34333571535

Reported net profit (INR Cr)

413-6573836398

Basic earnings per share (INR)

25.98-3.834.8452.6925.02

Diluted earnings per share (INR)

25.98-3.834.8452.6925.02

Dividend per share (INR)

5.005.005.005.005.00

Dividend payout ratio (%)

19-130102920

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (FY2023–FY2026)

MetricFY2023FY2024FY2025FY2026

EBITDA as reported by company (INR Cr)

8289941,2301,326

EBITDA margin as reported (%)

13.214.717.015.9

Normalised profit after tax (INR Cr)

00413442

Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Operating margin before other income (%)

18.812.413.416.215.2

Profit before tax margin (%)

10.30.42.513.67.4

Net profit margin (%)

6.7-1.01.111.64.8

Valuation Snapshot

MetricValue

Revenue CAGR FY2022–FY2026 (%)

7.8

Revenue CAGR FY2021–FY2026, five-year (%)

6.3

Revenue CAGR FY2023–FY2026, three-year (%)

9.6

Revenue growth FY2026 (%)

14.5

Trailing twelve-month revenue growth to Q1 FY2027 (%)

16.0

Share price, close 17 August 2026 (INR)

867

Market capitalisation (INR Cr)

13,832

Shares outstanding

159,281,140

Face value per share (INR)

1

52-week high (INR)

1,185

52-week low (INR)

784

Book value per share (INR)

445

Beta

1.34

Price to earnings, trailing (x)

35.6

Price to book (x)

1.95

Enterprise value to EBITDA, approximate (x)

12.1

Enterprise value to sales, approximate (x)

1.9

Dividend yield (%)

0.58

Earnings yield (%)

2.8

Balance Sheet

MetricFY2022FY2023FY2024FY2025FY2026

Total assets (INR Cr)

9,83010,92911,33812,58415,272

Equity share capital (INR Cr)

1616161616

Reserves and surplus (INR Cr)

5,3035,3835,4186,2397,077

Total shareholders equity (INR Cr)

5,3195,3995,4346,2557,093

Total borrowings (INR Cr)

3,1923,6773,6642,7313,615

Other liabilities (INR Cr)

1,3191,8532,2403,5984,564

Net fixed assets (INR Cr)

4,8715,1835,0915,1766,966

Capital work in progress (INR Cr)

1,0901,5622,1033,6304,040

Non-current investments (INR Cr)

239256424461

Other assets including current assets (INR Cr)

3,6313,9284,1013,7354,205

Cash Flow and Financial Ratios (x)

MetricFY2024FY2025Q3 FY2026

Net debt (INR Cr)

2,4571,3481,751

Net debt to equity (x)

0.450.220.28

Net debt to trailing EBITDA (x)

2.481.101.30

Interest coverage, EBITDA to interest (x)

3.705.106.30

Long-term capex creditors (INR Cr)

0453701

Cash Flow and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Cash from operating activities (INR Cr)

8386619711,0721,227

Capital expenditure (INR Cr)

5977968881,1101,347

Free cash flow (INR Cr)

241-13583-38-120

Cash from investing activities (INR Cr)

-323-474-596512-1,143

Cash from financing activities (INR Cr)

-33-157-432-1,45395

Net change in cash (INR Cr)

48230-58132179

Dividends paid (INR Cr)

8080808080

Share buybacks (INR Cr)

00000

Operating cash flow to operating profit (%)

90111131112114

Returns & Leverage Ratios (%) and Financial Ratios (x)

MetricFY2022FY2023FY2024FY2025FY2026

Return on equity on average equity (%)

8.2-1.21.314.36.0

Return on assets on average assets (%)

4.4-0.60.77.02.9

Return on capital employed (%)

1037109

Total debt to equity (x)

0.600.680.670.440.51

Interest coverage, EBITDA to interest (x)

7.94.13.75.16.3

Asset turnover on average assets (x)

0.660.610.600.600.59

Debtor days

5556504547

Inventory days

308268220178170

Days payable

139160146158170

Cash conversion cycle days

2241651246547

Working capital days

5657561613

Revenue by Region (%)

Metric9M FY2026

Share of revenue from United States (%)

81

Share of revenue from rest of world (%)

19

Share of revenue denominated in US dollars (%)

94

Share of revenue in other currencies (%)

6

Origin Details

OriginShare of US-destined revenue (%)

United States

74

Canada

17

India

9

Revenue by Region and Revenue by Region (%)

MetricFY2024FY2025FY2026

North America centric segment revenue (INR Cr)

4,7985,3616,230

North America centric share of total revenue (%)

71.674.175.2

India and rest of world centric segment revenue (INR Cr)

1,8691,8361,991

India and rest of world centric share of total revenue (%)

27.925.424.0

North America centric segment growth (%)

0.011.716.2

India and rest of world centric segment growth (%)

0.0-1.88.4

Capital Markets

MetricValue (%)

Share price CAGR, 10 years

7

Share price CAGR, 5 years

7

Share price CAGR, 3 years

26

Share price return, 1 year

-18

Per-Share Data and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Dividend per share (INR)

5.005.005.005.005.00

Dividend as percentage of face value (%)

500500500500500

Dividend payout ratio (%)

19-130102920

Total dividend outflow (INR Cr)

8080808080

Credit Ratings

AgencyInstrumentRatingOutlookDate

India Ratings & Research (Fitch Group)

Long-term issuer rating

IND AA+

Stable

Affirmed 5 May 2025; outlook revised to Stable 9 December 2024

India Ratings & Research

Bank facilities

IND AA+ / IND A1+

Stable

5 May 2025

India Ratings & Research

Commercial paper programme

IND A1+

—

Assigned 5 May 2025

India Ratings & Research

Rating update issued

Details not accessible

—

24 February 2026

CRISIL Ratings

Long-term bank facilities and NCDs

Withdrawn at company request

—

6 May 2021, following transfer of ₹460 crore of facilities to Jubilant Ingrevia

Analyst Conclusions

Management guidance

Management has issued no numeric guidance for FY2027. The qualitative commitments are precise enough to be testable:

  1. Growth momentum will strengthen in FY2027 relative to FY2026's 14.5%

  2. EBITDA margins will strengthen from H2 FY2027 as Montreal production stabilises

  3. Montreal operating losses will taper off in H2 FY2027; Montreal segment EBITDA breakeven targeted in FY2028

  4. Full SPECT product availability by H2 FY2027, with batch releases from Q2 FY2027

  5. Margin recovery will "effectively offset higher depreciation costs and drive net profit growth"

  6. Net debt to EBITDA to remain range-bound

  7. Line 3 commercial batch production from late FY2027 subject to FDA approval; Line 4 technology transfer revenue from Q4 FY2027

  8. Vision 2030: ₹13,500 crore revenue, 23–25% EBITDA margin, zero net debt, high-teens RoCE

Consensus growth expectations

The implied arithmetic of the Vision 2030 target requires a 13.0% revenue CAGR from FY2026 to FY2030 and 700–900 basis points of EBITDA margin expansion. Revenue is currently running ahead of that requirement (16% TTM). Margin is running 400 basis points behind the FY2024 starting point.

Three bull-case arguments

Bull 1 — The margin problem is dated, localised and already reversing. Every basis point of the FY2026 and Q1 FY2027 margin decline traces to one facility. Montreal has now completed media fills, resumed commercial batch production of SPECT products, and has batch releases scheduled for Q2 FY2027 with full availability in H2. Radiopharmaceuticals is a 40–47% margin business; restoring roughly ₹300 crore of annualised high-margin SPECT revenue mechanically restores 150–200 basis points of group margin. Meanwhile Spokane — the part of CDMO that is working — grew 43% with EBITDA up 49% at a 24% margin in Q1 FY2027. The underlying franchise did not deteriorate; one plant did.

Bull 2 — ₹4,040 crore of capital work in progress is a coiled spring. CWIP has risen 3.7x since FY2022 against 35% revenue growth. That capital is not lost — it is Lines 3, 4 and 5, six PET radiopharmacies and the CRDMO expansion, all with disclosed return targets above 20% RoCE and disclosed peak revenue potentials (US$160–180 million from Lines 3 and 4 alone, against total FY2026 CDMO revenue of ₹1,755 crore, or roughly US$195 million). As these assets commission, incremental revenue arrives at high incremental margin against already-charged depreciation. Group ROCE of 9% against a high-teens target is a measure of how much return is currently being withheld, not destroyed.

Bull 3 — Structural tailwinds are unusually well-aligned and rarely coincide. The US radiopharmaceutical market compounds at 20% toward US$20 billion by 2030, validated by US$9 billion of large-cap M&A in three years. The US sterile injectable market faces a 700-million-vial shortfall by 2027, made worse by Catalent's absorption into Novo Holdings. US tariff policy is actively pushing innovators to onshore, and Jubilant already has the isolator capacity in Washington State. The Biosecure Act redirects discovery demand to India, where Jubilant has 1,200 scientists and 8 of the top 20 pharma companies as clients. Each of these is independently powerful; together they are a rare configuration.

Three bear-case arguments

Bear 1 — The FDA pattern is the business risk, not an accident. Eight years, four sites, and a repeating cycle: Roorkee OAI (2018) → Warning Letter (2019) → import alert (2021) → six observations and OAI (2022) → VAI (2024); Montreal OAI (2023) → OAI again (2026) → Warning Letter (2026); Spokane eight observations (2026). Any individual event is defensible. The sequence suggests quality systems that repeatedly fall behind an escalating regulatory standard. The consequence is not merely lost quarters: under OAI the FDA may withhold approval of pending applications listing the facility — which is exactly the mechanism that could delay the nine-product FY2027–FY2029 pipeline on which one-third of the Vision 2030 revenue bridge depends.

Bear 2 — Free cash flow has been negative for two years and the balance sheet is absorbing it. FCF was −₹38 crore (FY2025) and −₹120 crore (FY2026). Borrowings rose ₹884 crore in FY2026. Long-term capex creditors rose from ₹453 crore to ₹701 crore in nine months. Net debt rose from ₹1,348 crore (March 2025) to ₹1,751 crore (December 2025) despite the FY2025 Sofie windfall of US$117 million. Depreciation rose 19% while EBITDA rose 8%. The company is paying an ₹80 crore dividend every year — including in a loss year — while running negative FCF and a Vision 2030 target of zero net debt. Those two commitments cannot both be met without a sharp and sustained inflection in operating cash generation.

Bear 3 — The largest business is economically inert and the fix is unproven. Radiopharmacy is 30% of group revenue at a 1.4% EBITDA margin. Vision 2030 requires it to reach 7–8% on a doubled revenue base — an outcome that depends entirely on six new PET sites, competing directly against a network with 160+ locations and 4,100 hospitals, in a segment where the company itself concedes "competitive intensity in SPECT radiopharmacy continues." If PET expansion delivers volume without margin — precisely the outcome of the last three years in that division — the group margin target is arithmetically unreachable and the multiple compresses toward the earnings.

Catalysts and monitorables for the next twelve months

TimingCatalystWhy it matters
Q2 FY2027 (Sep–Oct 2026)SPECT batch releases from MontrealThe first hard evidence the recovery is real, not scheduled
H2 FY2027Full SPECT product availability and the promised margin inflectionThe single most important number in the story
OngoingResolution of the Montreal Warning LetterUntil closed, pending applications listing the facility remain at risk
Within 15 business days of 17 Jun 2026, then follow-upSpokane response to 8 observations and the resulting classificationSpokane is now the growth engine; an OAI here would be far more damaging than Montreal
Late FY2027Line 3 commercial batch production, subject to FDA approvalConverts technology-transfer revenue into higher-margin commercial revenue
Q4 FY2027Line 4 technology transfer revenue commencementConfirms the capacity pipeline is on schedule
Dec 2026Pantoprazole final approval on RLD patent expiryRoughly US$40–45 million addressable; validates the Roorkee restart
Sep 2026MIBG pre-NDA meeting with FDAGates an NDA filing in H2 FY2027 for a US$70–100 million peak-sales asset
CY2026JBI-802 and JBI-778 clinical data readoutsThe trigger for the stated monetisation exploration
FY2028 (progress reported quarterly)PET radiopharmacy site commissioning, 3 to 9The single largest lever in the Vision 2030 margin bridge
Each quarterFree cash flow, net debt and capex creditorsDetermines whether the zero-net-debt target survives contact with the capex programme
Each quarterRuby-Fill install base growthRan 21%, then 35%, then 26% YoY; deceleration would signal Lantheus competitive pressure
Aug 2027 (Aug 2026 baseline)US generic import tariff, effective after a two-year grace periodDirectly affects the Roorkee-based US generics plan
OngoingNew permanent CFO's first full reporting cycleThird CFO in three years; execution credibility matters

Concluding analyst verdict

Jubilant Pharmova is a company whose assets are considerably better than its arithmetic, and the gap between the two is the entire investment case.

The asset base is genuinely hard to replicate. A radiopharmaceutical franchise with a US monopoly product, the number-two US radiopharmacy network, a sole-supplier position in venom immunotherapy, and onshore US sterile fill-finish capacity at precisely the moment tariff policy rewards it — that combination does not exist elsewhere in the Indian listed universe and barely exists globally. The moats are structural rather than contractual: nuclear licences, 4,000-hour pharmacist certifications, 18-to-24-month technology transfers, isotope half-lives measured in hours. These are not eroded by a bad quarter.

The arithmetic is where the problem sits. Revenue growth accelerated to 14.5% in FY2026 and 17% in Q1 FY2027 — the best in the post-demerger era. Yet EBITDA margin fell 99 basis points in FY2026 and a further 385 basis points in Q1 FY2027, free cash flow was negative for a second consecutive year, borrowings rose ₹884 crore, and RoCE of 9% remains below the FY2022 level. The company has invested ₹4.4 crore of capital work in progress for every ₹1 crore of incremental FY2026 revenue. Management's explanation — Montreal — is honest, specific and largely correct. But it is also the third distinct FDA-driven earnings disruption in eight years, at the third distinct facility, and that changes it from bad luck into a risk factor requiring a probability weighting rather than an apology.

The resolution is not far away and is unusually testable. By H2 FY2027 investors will know whether SPECT supply has fully normalised, whether the margin inflection management has promised actually arrives, whether Spokane's eight observations resolve benignly, and whether the first PET radiopharmacies commission on schedule. Those four outcomes will determine whether Vision 2030's 23–25% EBITDA margin is a plan or an aspiration.

At 35.6x trailing earnings and roughly 12x EV/EBITDA, with the stock 30% below its all-time high and foreign institutions having exited 733 basis points of the register over three years, the market is pricing meaningful scepticism about execution while still paying a specialty-pharma multiple for the franchise. That is, on balance, a fair place for it to sit. The appropriate posture is constructive but conditional: the franchise merits a premium, the capital cycle merits patience, and the compliance record merits a discount. Investors should size positions to the recognition that the single most important variable — an FDA classification at a Canadian plant — is not within management's control, and that the company has not yet demonstrated it can hold three regulated sites clean simultaneously through a period of heavy expansion.


APPENDIX A — DATA SOURCES AND CONFIDENCE NOTES

Primary sources relied upon: Jubilant Pharmova quarterly results releases and earnings presentations (Q3 FY2026 earnings presentation used extensively for segment, market-sizing and Vision 2030 data); Q4/FY2026 results release (22 May 2026); Q1 FY2027 results release (10 August 2026); Q2 FY2026 press release (31 October 2025); Annual Report 2023-24; company websites (jubilantpharmova.com, jubilantpharma.com, jubilantbiosys.com, jubilanttx.com); BSE and NSE regulatory filings as summarised by financial data providers; India Ratings & Research and CRISIL Ratings public rating actions; postal ballot notice (July 2026).

Secondary sources: screener.in (consolidated financial statement series FY2015–FY2026, sourced from company filings via C-MOTS Internet Technologies); trendlyne (shareholding pattern detail); Business Standard, ANI, Indian Pharma Post, Medical Dialogues, EquityBulls, Business Upturn, ScanX and other Indian financial media for event-level newsflow; Sustainalytics; Tracxn (MCA registry data).

End of dossier.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Board of Directors

NameRoleOn board sinceNotes

Shyam S. Bhartia

Chairman

Founder

Co-founder of the Jubilant Bhartia Group; 44+ years of experience across pharma, specialty chemicals, foods, oil and gas, aerospace and IT; age approximately 74

Hari S. Bhartia

Co-Chairman, Non-Executive Director

Founder

Co-founder; 38+ years of experience across the same sectors; served as Managing Director until 31 May 2023; Chairman of Jubilant Therapeutics Inc.; age approximately 70

Priyavrat Bhartia

Managing Director

May 2017 (as NED); MD from 1 Jun 2023

Son of Shyam S. Bhartia. Age 49. BA Economics, Dartmouth College; MBA, Stanford University. c.29 years of industry experience. Also on the boards of Jubilant Ingrevia, Jubilant Industries, HT Media, Digicontent and Hindustan Media Ventures. Reappointed for three years from 1 June 2026

Arjun Shanker Bhartia

Joint Managing Director

May 2017 (as NED); Joint MD from 1 Jun 2023

Son of Hari S. Bhartia. Age 39. Graduate of Brown University (2008). Associate Consultant at Bain & Company 2008–2010. Also on the boards of Jubilant Consumer and Jubilant Enpro. Reappointed for three years from 1 June 2026

Arvind Chokhany

Group Chief Financial Officer and Whole-Time Director

Whole-time Director; DIN 06668147

Group CFO of the Jubilant Bhartia Group; served as Jubilant Pharmova CFO from 1 June 2023 until the interim CFO appointment of October 2025

Vivek Mehra

Independent Director

——

Sushil Kumar Roongta

Independent Director

——

Arun Seth

Independent Director

——

Shirish Gundopant Belapure

Independent Director

——

Ramakrishnan Arul

Independent Director

——

Harsh Mahajan

Independent Director

——

Shivpriya Nanda

Independent Director

—

Woman director

“—” = not publicly disclosed.

Executive Leadership Team

NameRole

Priyavrat Bhartia

Managing Director

Arjun S. Bhartia

Joint Managing Director

Arvind Chokhany

Group CFO, Whole-Time Director

Ashish Mukkirwar

Chief Financial Officer (effective 23 May 2026)

Shantanu Jha

Group Chief Human Resources Officer

Dr Tushar Gupta

Head — Corporate Strategy

Harsher Singh

CEO — Jubilant Radiopharma

Chris Preti

CEO — CDMO Sterile Injectables (Jubilant HollisterStier)

Kyle Ferguson

CEO — Allergy Immunotherapy

Giuliano Perfetti

CEO — CRDMO, Jubilant Biosys

Dr Jaidev Rajpal

CEO — Jubilant Generics

Daniel J. O'Connor

President and CEO — Jubilant Therapeutics Inc. (effective 1 December 2025)

Prakash Bisht

Executive Vice President — Group Accounts

Surajit Pal

Head of Investor Relations

Naresh Kapoor

Company Secretary and Compliance Officer

Directors' Remuneration

ExecutiveSalary (INR Mn)Total compensation (INR Mn)Salary share of total (%)

Priyavrat Bhartia, Managing Director

25.067.537.1

Arjun S. Bhartia, Joint Managing Director

0.067.50.0

Arvind Chokhany, Group CFO and WTD

0.044.80.0

Shareholding Trend

Holder categorySep 2023Mar 2024Mar 2025Mar 2026Jun 2026

Promoter and promoter group (%)

50.6750.6750.6747.6747.67

Foreign institutional investors (%)

23.2019.0617.2315.9015.87

Domestic institutional investors (%)

1.643.777.0511.6312.40

Public and non-institutional (%)

23.8925.9124.4824.2523.50

Others including employee benefit trust (%)

0.590.580.560.560.55

Number of shareholders

89,37692,26496,52686,34782,703

Governance Detail

Promoter entityHolding (%)Shares

SPB Trustee Company Pvt Ltd

20.5232,686,161

HSB Trustee Company Pvt Ltd

19.0030,257,475

Miller Holdings Pte Ltd (foreign)

3.285,230,455

MAV Management Advisors LLP

3.155,011,400

Nikita Resources Private Limited

2.203,504,540

Jubilant Enpro Private Limited

1.332,116,000

Priyavrat Bhartia

0.881,398,010

Hari Shanker Bhartia

0.23360,885

Shamit Bhartia

0.08129,245

Kavita Bhartia

0.0110,285

Major Shareholders

HolderTypeHolding (%)Shares

East Bridge Capital Master Fund I Ltd

FPI

3.926,241,736

Government Pension Fund Global (Norges Bank)

FPI

3.455,502,797

Estate of Late Mr Rakesh Jhunjhunwala

Public individual

3.285,224,000

Rekha Jhunjhunwala

Public individual

3.155,020,000

Quant Mutual Fund — Quant Small Cap Fund

Domestic MF

1.923,059,145

SBI Life Insurance Co. Ltd

Domestic insurer

1.392,219,866

Theleme India Master Fund Limited

FPI

1.322,107,924

Abakkus Emerging Opportunities Fund-1

AIF

1.201,909,849

Investor Education and Protection Fund

Statutory

1.251,994,498

Competitive Landscape

Competitor Detail

NetworkRadiopharmaciesSPECT capablePET capableHospitals served

Largest competitor (Cardinal Health)

160+

Yes

Yes

~4,100

Jubilant Radiopharmacies

45

Yes

Yes

~1,800

Competitor 3

41

Yes

No

~700

Competitor 4

31

Yes

No

~900

Competitor 5

42

Yes

Yes

~200

Competitor 6

14

Yes

No

~200

Competitor Detail (Annual)

MetricJubilant Pharmova FY2026

Revenue (INR Cr)

8,280

Revenue growth (%)

14.5

EBITDA margin (%)

15.9

Net profit margin (%)

4.8

Return on capital employed (%)

9.0

Recent Developments

--

Company Snapshot

$956.1M

Revenue

5,500

Employees

$1,600M

Market Cap

1978

Founded

Uttar Pradesh, India

Headquarters

SWOT Analysis

Strengths

  • Monopoly and near-monopoly product positions: HICON Sodium Iodide I-131 has "no direct competition in the US market"; Jubilant is the sole US supplier of venom immunotherapy extracts among a three-player market
  • The second-largest US radiopharmacy network, with a scale gap to the number three: 45 sites (42 SPECT, 3 PET), 1,800 hospitals, approximately 20% volume share, versus 41 sites and 700 hospitals for the next-largest SPECT-only network
  • Exceptional operating margins in the core specialty franchise: Radiopharmaceuticals EBITDA margin of 50% (FY2024), 47% (FY2025), 44% (9M FY2026); Allergy Immunotherapy 35–40%
  • Demonstrated capacity execution at Spokane: Spokane revenue +48% in FY2026 to ₹1,714 crore, EBITDA +59% to ₹463 crore, margin +190 bps to 27%; management describes "one of the fastest revenue ramp-ups in the industry"
  • Contractual lock-in with blue-chip customers: 5 of the top 20 pharma as CDMO customers; 92% retention; 90%+ repeat business; 5+ year average relationship with the top ten; 18–24 month switching time
  • Balance sheet repaired and working capital transformed: Net debt fell from ₹2,457 crore (FY2024) to ₹1,348 crore (FY2025); cash conversion cycle compressed from 224 days (FY2022) to 47 days (FY2026); working capital days from 56 to 13
  • Subsidised growth capital: US$149.6 million BARDA/US Army cooperative agreement for Spokane; CAD 25 million Quebec loan with a CAD 6.3 million forgivable portion; US$35 million concessional loan for Montreal Line 5
  • Investment-grade credit standing maintained through the capex cycle: IND AA+/Stable long-term issuer rating and IND A1+ short-term, affirmed May 2025

Weaknesses

  • A recurring, multi-site pattern of FDA compliance failures: Roorkee OAI (Dec 2018), Warning Letter (Mar 2019), import alert (Jul 2021), six observations and OAI (2022); Montreal OAI (May 2023), OAI again (Feb 2026), Warning Letter (Q1 FY2027); Spokane 8 observations (Jun 2026)
  • The largest business by revenue earns almost nothing: Radiopharmacy generated ₹2,512 crore of FY2026 revenue at ₹36 crore of EBITDA — a 1.4% margin on 30% of group revenue
  • Two consecutive years of negative free cash flow: FCF of −₹38 crore (FY2025) and −₹120 crore (FY2026), with capex of ₹1,110 crore and ₹1,347 crore respectively
  • ₹4,040 crore of capital work in progress earning nothing: CWIP has risen 3.7x since FY2022 while revenue rose 35%; RoCE of 9% in FY2026 remains below the FY2022 level of 10%
  • Margin decline is now a multi-quarter trend, not an event: EBITDA margin: Q2 FY2026 17.8%, Q3 FY2026 14.5%, Q4 FY2026 15.7%, Q1 FY2027 11.9%
  • Executive instability in the finance function: Three CFO changes in three years: Arun Kumar Sharma out (May 2023), Arvind Chokhany in, Arun Kumar Sharma back on an explicitly interim basis (Oct 2025), Ashish Mukkirwar in (May 2026)
  • Consolidated R&D expenditure is not disclosed: Absent from all investor materials reviewed; a notable gap for a company whose thesis depends on new product launches
  • Reported earnings quality has been poor: FY2025 net profit of ₹836 crore included ₹382 crore of net exceptional income; FY2024 net profit of ₹73 crore was below the ₹80 crore dividend paid

Opportunities

  • A US radiopharmaceutical market compounding at 20% toward US$20 billion by 2030: Company disclosure; validated by four billion-dollar radiopharma acquisitions by Novartis, AstraZeneca, Lilly and BMS
  • Six new PET radiopharmacies at 20%+ RoCE on US$50–60 million: The single largest lever in the Vision 2030 margin bridge, taking Radiopharmacy from 1% to 7–8% EBITDA margin
  • Nine new PET and SPECT product launches FY2027–FY2029 across a US$550 million incremental TAM: US$120 million potential peak annual sales
  • MIBG in relapsed/refractory paediatric neuroblastoma: Phase 2 dosing complete; NDA filing H2 FY2027; launch CY2027; potential peak sales US$70–100 million in an indication with limited treatment options
  • US onshoring driven by tariff policy: 700 million vial supply gap by 2027; management reports "strong traction in requests for proposals" specifically for isolator-based US sterile capacity
  • Lines 3, 4 and 5 together represent a doubling of Spokane capacity plus new Montreal capacity: Combined Line 3 and 4 potential of US$160–180 million; Line 5 adds further from FY2029
  • Biosecure Act friendshoring into Indian CRDMO: 8 of the top 20 pharma already customers, with a 5x increase in large-pharma revenue share; FTE capacity roadmap from 1,000 to 4,000 by FY2030
  • Novel drugs monetisation: JBI-802 and JBI-778 hold FDA Orphan Drug designations across indications with a combined stated US TAM above US$10 billion; data readouts expected CY2026; a biotech-experienced CEO installed December 2025

Threats

  • The Montreal Warning Letter could persist or escalate: Received Q1 FY2027 following the February 2026 OAI; under OAI the FDA "may withhold approval of any pending applications or supplements in which this facility is listed" — which would directly delay the nine-product FY2027–FY2029 launch pipeline
  • Single-point manufacturing dependency for the entire SPECT franchise: Montreal is the sole manufacturing site; alternate CMOs are still under development, not in place
  • Competitive entry into protected products: Generic entry into DTPA occurred during FY2026 and was explicitly cited as a drag on Radiopharmaceuticals revenue growth
  • Direct competition in cardiac PET from a well-capitalised specialist: Lantheus competes head-to-head in Rb-82 generators, and the FY2026 disclosure notes "competitive intensity in SPECT radiopharmacy continues"
  • US tariff escalation on generic pharmaceuticals: Reported 200% tariff on generic drug imports after a two-year grace period from August 2026, placing India's US$9.7 billion of exports at risk; Jubilant's exposure is limited to c.3% of US-destined revenue but the Roorkee-based generics growth plan is directly in scope
  • Isotope supply disruption: Global Mo-99 supply is tied to research reactor uptime; the company itself identifies this as a principal supply risk
  • Modality substitution: Emerging non-radioactive imaging techniques could erode conventional tracer demand over a multi-year horizon
  • Execution risk on a capital programme that has already doubled the balance sheet: ₹4,040 crore of CWIP, rising borrowings (+₹884 crore in FY2026), rising capex creditors (₹701 crore at Dec 2025 versus ₹453 crore at Mar 2025), and depreciation rising 19% while EBITDA rose 8%

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
Feb 2025Q3 FY2025 results published; investor and analyst meet held (transcript dated 4 March 2025)Set up the FY2025 recovery narrative
13 Mar 2025Salisbury, Maryland facility receives USFDA Voluntary Action Indicated (VAI) classificationRemoves regulatory risk from the US solid-dosage site
5 May 2025India Ratings assigns commercial paper IND A1+; affirms bank facilities at IND AA+/StableConfirms investment-grade standing through the capex cycle
16 May 2025Q4 and FY2025 results. Q4 revenue ₹1,915.8 crore (+9.7%), net profit ₹153.6 crore versus a ₹58.6 crore loss in Q4 FY2024; Q4 EBITDA ₹357 crore (+23%), margin 18.4%. FY2025 revenue ₹7,192.1 crore, net profit ₹839.4 crore (+988.7%). Dividend ₹5 per shareStock rallied 4.54% to ₹947.05. Headline profit surge driven by the Sofie disposal, not operations
12 Jun 2025Board approves slump sale of the API business to Jubilant Biosys LimitedConsolidates the end-to-end CRDMO platform
13 Jun 2025Promoter block deal: Jubilant Enpro and Nikita Resources sell 3,286,000 shares (2.06%). Part of a ₹1,801 crore group-wide sale across three listed entities. Stock rose 3.96% intraday to ₹1,170 on the API newsPromoter holding falls from 50.67% to 47.67%
Jul 2025Q1 FY2026 results: revenue ₹1,901 crore, net profit ₹102 crore—
2 Aug 2025Pre-Approval Inspection completed by USFDA at the Roorkee solid dosage facilityPrecondition for the subsequent Pantoprazole approval
29 Aug 202547th Annual General Meeting held—
23 Sep 2025Board approves Arun Kumar Sharma as CFO and KMP effective 1 October 2025, on an interim basis pending identification of a permanent CFOA CFO vacancy filled on an explicitly temporary basis is a governance signal worth noting
Oct 2025Spokane Line 3 launched — US$132 million, isolator technology, +50% capacity, inaugural batch produced. Chris Preti: "a defining moment in Jubilant HollisterStier's journey"The single most important operational event of the period
31 Oct 2025Q2 and H1 FY2026 results: Q2 revenue ₹1,966 crore (+12%), EBITDA ₹351 crore (+13%), normalised PAT ₹124 crore (+21%). H1 revenue ₹3,867 crore (+11%), EBITDA ₹653 crore (+13%), normalised PAT ₹227 crore (+32%). Net debt ₹1,897 crore. API transfer to Jubilant Biosys confirmed completeBest margin quarter of the year; the peak before the Montreal disruption
4 Nov 2025Company discloses USFDA audit of the CMO Montreal facility conducted October–November 2025First public signal of the impending problem
Nov–Dec 2025Montreal CMO facility temporarily shut for remediation following FDA observations; internal quality system improvements and facility upgrades initiatedRemoves high-margin SPECT supply for two-plus quarters
1 Dec 2025 (announced 5 Dec)Daniel J. O'Connor appointed President and CEO of Jubilant Therapeutics Inc.Signals intent to monetise the novel drugs pipeline
12 Jan 2026Jubilant Biosys opens new discovery and preclinical facility at Noida, doubling overall chemistry capacity for discovery research and scale-up; multimillion-dollar investment with R&D labs and two pilot plantsCapacity ahead of demand in the fee-for-service model
Feb 2026Q3 and 9M FY2026 results: Q3 revenue ₹2,123 crore (+17%), EBITDA ₹310 crore (+5%), margin 14.5% (−172 bps), normalised PAT ₹86 crore (−17%), reported PAT ₹56 crore. Exceptional expense includes ₹13 crore for the new labour code wage definition and ₹26 crore for the Montreal suspension. Net debt/EBITDA 1.3x (down from 1.5x in Sep)First quarter where Montreal materially damaged reported margins
12 Feb 2026USFDA classifies the CMO Montreal facility as "Official Action Indicated" (OAI) following the October–November 2025 inspection. Communication received 12 February 2026 at 10:08 PSTEscalation. Under OAI the FDA may withhold approval of pending applications listing the facility
24 Feb 2026India Ratings issues a rating update on Jubilant Pharmova–
Apr 2026USFDA approval received for Dextroamphetamine SaccharateAdds to the CNS generics portfolio
22 May 2026Q4 and FY2026 results. FY revenue ₹8,279.6 crore (+14%), total income ₹8,346 crore, EBITDA ₹1,325.5 crore (+8%), margin 15.9%, normalised PAT ₹442.4 crore (+7%), reported consolidated PAT ₹397.5 crore. Q4 revenue ₹2,290 crore (+19%), EBITDA ₹363 crore (+2%), normalised PAT ₹129 crore. Dividend ₹5 per share. Vision 2030 reaffirmedRecord revenue with contracting margin — the defining tension of the current story
22 May 2026CFO transition: Arun Kumar Sharma relinquishes the CFO role and becomes Advisor to the Chairmen; Ashish Mukkirwar appointed CFO and KMP effective 23 May 2026Second CFO change in eight months
22 May 2026Board approves reappointment of Priyavrat Bhartia as MD and Arjun Shanker Bhartia as Joint MD for three years from 1 June 2026, subject to shareholder approvalLeadership continuity through the Vision 2030 window
22 May 2026Statutory auditors Walker Chandiok & Co. LLP issue an unmodified opinion on FY2026 standalone and consolidated resultsClean audit
17 Jun 2026USFDA inspection at Spokane concludes with 8 observations, none related to sterility assurance. Company to respond within 15 business daysGiven Spokane is now the group's growth engine, this is a material watch item
25–26 Jun 2026Tentative USFDA approval for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet (Jubilant Generics). Final approval expected on reference-drug patent expiry December 2026. US market for the dosage form estimated at US$40–45 millionDirect payoff from the August 2025 Roorkee PAI
Q1 FY2027FDA Warning Letter received for the CMO Montreal facilityEscalation beyond OAI. Remediation underway
Q1 FY2027Media fills successfully completed at CMO Montreal; commercial batch production for SPECT radiopharmaceuticals begins. Batch releases slated Q2 FY2027; full product availability H2 FY2027The recovery path is now concrete rather than aspirational
Q1 FY2027Jubilant Pharmova receives tax relief; a ₹22 crore claim is deletedModest but positive
19 Jul – 17 Aug 2026Postal ballot for MD and Joint MD reappointments (record date 10 July 2026); outcome and scrutinizer's report filed 17 August 2026—
24 Jul 2026Dividend of ₹5.00 per share due—
10 Aug 2026Q1 FY2027 results: revenue ₹2,229 crore (+17%), total income ₹2,249 crore, operating EBITDA ₹268 crore (−11%), margin 11.9% (−385 bps), reported net profit ₹56 crore (−45%). CDMO revenue ₹496 crore (+34%); Spokane revenue ₹494 crore (+43%), EBITDA ₹117 crore (+49%), margin 24%. Radiopharmaceuticals ₹322 crore (+19%). Radiopharmacy ₹700 crore (+17%). Allergy ₹214 crore (+18%). Drug Discovery ₹174 crore (+8%), EBITDA ₹45 crore (+43%), margin 26%. API ₹135 crore. Generics ₹173 crore (+4%). Line 4 installation complete; 10+ products in tech transfer on Line 3Growth intact, profitability impaired. Margin down for a third consecutive quarter
Aug 2026Systematix names Jubilant Pharmova among preferred picks (with Sun Pharma and Cipla) ahead of Q1 FY2027 results, on a thesis of domestic-focused pharma outperforming amid US generics pressureSell-side sentiment remains constructive despite the earnings miss
26 Aug 202648th Annual General Meeting scheduled—

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

3 charts
Revenue by Region: North America centric segment revenue rose from INR 47,980 Mn in FY2024 to INR 62,300 Mn in FY2026.
Jubilant Pharmova Limited — Revenue by Region
Series (INR Mn)FY2024FY2025FY2026
North America centric segment revenue47,98053,61062,300
India and rest of world centric segment revenue18,69018,36019,910

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.